Background: EUS-guided FNA (EUS-FNA) is a sensitive test for the preoperative diagnosis of pancreatic cancer. Its use for diagnosing local tumor recurrence after surgical resection has not been described.
Objective: To determine the sensitivity of EUS-FNA for this indication.
Design: Retrospective cohort study.
Setting: Tertiary referral hospital in the United States.
Patients: Consecutive patients referred for EUS with clinical and/or radiographic suspicion of pancreatic cancer recurrence.
Interventions: EUS ± FNA of retroperitoneal mass.
Main Outcome Measurement: Sensitivity of EUS-FNA.
Results: Seventeen patients (9 male, median age 71 years) underwent EUS at a median of 17 months (range 7-46 months) after a classic Whipple procedure (n = 7), pylorus-sparing Whipple procedure (n = 7), or distal pancreatectomy (n = 3) for suspected local recurrence of pancreatic cancer. The primary tumor (median size 2.5 cm, range 1.5-7.9 cm) was located in the head in 14 patients, the body in 1, and the tail in 2. Final surgical margins at any site were positive in only 1 of 17 patients (+ retroperitoneal margin). At the time of suspected recurrence, 4 patients (24%) were asymptomatic. EUS disclosed a mass (median size 21 mm, range 12-30 mm) in 16 of 17 patients (94%). Transgastric EUS-FNA (n = 16, median 4.5 passes, range 2-10) disclosed recurrent malignancy in 13 of 16 (79%), atypical cells in 1 of 16 (7%), and benign cytology in 2 of 16 (14%). Subsequent radiographic evidence of increasing tumor burden was seen in 1 of 2 patients with benign cytology; however, follow-up for the 2 other patients with benign biopsy specimens was not available. Depending on the status of the 2 patients without available follow-up, the sensitivity, specificity, and accuracy of EUS-FNA for the diagnosis of recurrent cancer ranged from 81% to 93%, was 100%, and ranged from 81% to 93%, respectively.
Limitations: Small, single-center retrospective cohort.
Conclusions: EUS-FNA is sensitive for the diagnosis of retroperitoneal recurrence of pancreatic cancer after surgical resection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.gie.2010.07.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ASO Visual Abstract: Survival of Patients with Resected Microsatellite Instability-High, Mismatch Repair Deficient, and Lynch Syndrome-Associated Pancreatic Ductal Adenocarcinomas.
Ann Surg Oncol
January 2025
Hepato-Pancreato-Biliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Improving molecular subtypes and prognosis of pancreatic cancer through multi group analysis and machine learning.
Discov Oncol
January 2025
Department of Laboratory, the Second Hospital of Shanxi Medical University, No. 382, Wuyi Road, Taiyuan, 030001, Shanxi, People's Republic of China.
Background: Pancreatic cancer (PAC) has a complex tumor immune microenvironment, and currently, there is a lack of accurate personalized treatment. Establishing a novel consensus machine learning driven signature (CMLS) that offers a unique predictive model and possible treatment targets for this condition was the goal of this study.
Methods: This study integrated multiple omics data of PAC patients, applied ten clustering techniques and ten machine learning approaches to construct molecular subtypes for PAC, and created a new CMLS.
mSphere of Influence: Seeking the unseen fungi in tumors.
mSphere
January 2025
State Key Laboratory of Systems Medicine for Cancer, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ningning Liu works in the field of fungal infection and cancer progression, with a particular focus on the mechanism of host-pathogen interaction. In this mSphere of influence article, he reflects on how papers entitled "The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL," by B. Aykut, S.
View Article and Find Full Text PDFConcerns about needle tract seeding after endoscopic ultrasound-guided tissue acquisition: A possibility not limited to pancreatic body and tail cancer.
J Hepatobiliary Pancreat Sci
January 2025
Department of Gastroenterology, Shizuoka General Hospital, Shizuoka, Japan.
Physical Activity and Incident Pancreatic Cancer: Results From the UK Biobank Prospective Cohort.
Cureus
January 2025
Hepato-Pancreato-Biliary (HPB) Unit, University Hospital Southampton NHS Foundation Trust, Southampton, GBR.
Background The relationship between physical activity and incident pancreatic cancer is poorly defined, and the evidence to date is inconsistent, largely due to small sample sizes and insufficient incident outcomes. Using the UK Biobank cohort dataset, the association between physical activity levels at recruitment and incident pancreatic ductal adenocarcinoma (PDAC) at follow-up was analysed. Method Physical activity, the key exposure, was quantified using Metabolic Equivalent Task (MET) values and categorised into walking, moderate, and vigorous activity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!